Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.620
+0.040 (1.12%)
At close: Apr 1, 2026, 4:00 PM EDT
3.610
-0.010 (-0.28%)
After-hours: Apr 1, 2026, 7:59 PM EDT
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Rocket Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $29.73, which forecasts a 721.27% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $263.
Price Target: $29.73 (+721.27%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $8 → $9 | Strong Buy | Maintains | $8 → $9 | +148.62% | Mar 30, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +203.87% | Mar 27, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $2 → $3 | Strong Sell | Maintains | $2 → $3 | -17.13% | Mar 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +176.24% | Feb 27, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +120.99% | Nov 18, 2025 |
Financial Forecast
Revenue This Year
19.36M
Revenue Next Year
29.27M
from 19.36M
Increased by 51.17%
EPS This Year
-1.55
from -2.01
EPS Next Year
-1.25
from -1.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 150.2M | 136.5M | |||
| Avg | 19.4M | 29.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 604.9% | |||
| Avg | - | 51.2% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.06 | -0.78 | |||
| Avg | -1.55 | -1.25 | |||
| Low | -1.79 | -1.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.